PATENT CLAIM ANALYSIS

Application Number: 15772554
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "262100"]

Abstract:
A compound, or a pharmaceutically acceptable salt thereof, having a chemical structure of formula (I) or formula (II), and methods of using these compounds to treat cancer in an individual.

Claim (Index 20):
The method of  claim 18 , wherein the pharmaceutical composition is administered in combination with one or more DNA-targeted agents, including DNA alkylating agents and topoisomerase inhibitors, including cisplatin, capecitabine, carboplatin, cyclophosphamide, cytarabine, dauoribicin, docetaxel, doxorubicin, 5-fluorouracil, gemcitabine, methotrexate, paclitaxel, premetrexed, irinotecan temozolomide, topotecan, radiation, or combinations thereof.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 93.0
- Lexical Diversity: 1.26667
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14381151', '11908395', '12310150', '13754499', '11282119']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7970007306233278
- 35 USC 102 Novelty (BERT): 0.52028744698513
- Combined Prediction Score: 0.7693294022595081
- Mean Citation Score: 293.29403799999994
- Max Citation Score: 311.37302
- Similarity Product: 211.8412810816836

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test